F2G: Funding, Investors & Team (Sep 2026)
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.
F2G has raised $131M across 2 funding rounds on record, the most recent a Private Equity of $70.0M announced in Aug 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
F2G Company Profile and Key Stats
Latest funding round on record: Aug 2022.
F2G Funding Rounds
F2G raised $60.8M in an undisclosed round announced in Aug 2020.
2 years later, a Private Equity of $70.0M was announced in Aug 2022.
F2G Founders and Leadership Team
Contact details for the F2G team: 1 of 1 has an email address on file.
Start 14-day free trial →F2G Funding Compared to Other Biotechnology Startups
F2G's latest round of $70.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like F2G in Biotechnology and Manchester
Companies Similar to F2G
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
F2G Funding FAQs
What does F2G do?
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.
How much funding has F2G raised?
F2G has raised $131M across 2 rounds on record. The most recent is a Private Equity of $70.0M announced in Aug 2022.
When did F2G last raise funding?
F2G's most recent funding round on record is a Private Equity of $70.0M, announced in Aug 2022.
Who is the CEO of F2G?
Ian Nicholson is listed as CEO at F2G.
Where is F2G headquartered?
F2G is based in Manchester, United Kingdom.
How many employees does F2G have?
F2G is in the 251-500 employee band.
How does F2G's funding compare to other Biotechnology startups?
F2G's latest round of $70.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's F2G Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for F2G is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.